FOFlavia Amadeu de Oliveira

Flavia Amadeu de Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Flavia Amadeu de Oliveira has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PHOSPHO1 deficiency delays osteogenic differentiation of osteoblasts, impairing mineralization and altering the protein composition of matrix vesicles

    by Luiz Henrique da Silva Andrilli, Cintia Kazuko Tokuhara, Larwsk Hayann Silva, Angie Puelles, Colin Farquharson, Ana Paula Ramos, Jose Luis Millán, Flavia Amadeu de Oliveira, Pietro Ciancaglini

    Matrix vesicles (MVs), a specialized class of extracellular vesicles, play a central role in skeletal mineralization. Phosphoethanolamine/phosphocholine phosphatase 1 (PHOSPHO1) generates inorganic phosphate (Pi) within the MV lumen and is considered essential for the initiation of mineralization. This study investigated the role of PHOSPHO1 in osteoblast differentiation and MV biology using primary calvariae osteoblasts from 6-day-old wild-type (WT) and Phospho1-/- mice. Cells were cultured under osteogenic conditions for 14 and 21 days, followed by analyses of cell viability, mineralization, gene expression, MV biophysical properties, and proteomic analyses. Phospho1-/- osteoblasts exhibited threefold higher mitochondrial activity than WT cells. Mineral deposition was detected only in WT cultures at day 21, indicating impaired mineralization in the absence of PHOSPHO1. Gene expression analysis revealed increased Alpl and Smpd3, and decreased Enpp1 expression in Phospho1-/- osteoblasts. Consistent with these findings, alkaline phosphatase (ALP) activity in MVs increased 7.5-fold between days 14 and 21 in both genotypes. Atomic force microscopy of MVs derived from Phospho1-/- osteoblasts exhibited a 6.5- and 2.1-fold reduction in vesicle volume and surface roughness, respectively, compared with WT MVs. Proteomic analysis revealed reduced tissue non-specific alkaline phosphatase (TNAP) at day 14, followed by increased TNAP levels at day 21, accompanied by decreased collagen XII and collagen VI content in Phospho1-/- MV preparations. Collectively, these findings indicate that cellular adaptation is insufficient to restore mineralization in the absence of PHOSPHO1. Instead, PHOSPHO1 appears to play a critical role in establishing the molecular and biophysical properties of MVs necessary for mineral nucleation and propagation.

  • Open Access

    Effects of comorbid chronic kidney disease on late-onset hypophosphatasia mice under treatment with asfotase alfa

    by Cintia Tokuhara, Flavia Amadeu de Oliveira, Sonoko Narisawa, Elis J Lira dos Santos, Brian L Foster, Jose Luis Millan

    Hypophosphatasia (HPP) is a rare bone disorder caused by loss-of-function mutations in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (TNAP) activity and impaired skeletal/dental mineralization. Asfotase alfa (AA), the only FDA-approved therapy, improves survival and skeletal/dental mineralization. Because of its mineral-binding properties, AA also binds to sites of ectopic calcification, including vasculature. Overexpression of TNAP in either the vascular media or intima has been shown to induce severe calcification. Here, we examined what might occur if a disease that features medial artery calcification, such as CKD-mineral and bone disorder (CKD-MBD), were to develop in a subject with HPP undergoing AA treatment. Two-month-old AlplPrx1/− (HPP) or Alplflox/− (non-HPP control) mice were treated with s.c. AA injections (8.2 mg/kg, 3×/week) for 4 mo. After 3 mo of treatment, CKD was induced via a 0.2% adenine and 1.8% phosphorus diet. Mice were euthanized at 6 mo of age, and skeletal, renal, cardiac, and vascular tissues were analyzed. Alkaline phosphatase levels slightly increased with AA but significantly increased after inducing CKD in control and HPP female mice. In males, ALP activity was elevated in the AA and AA+CKD cohorts. Micro-CT analysis showed improved bone parameters in HPP under AA treatment. However, the improvements were dampened when CKD was induced, compared to non-CKD Alplflox/−. Immunohistochemistry of the kidney revealed increased TNAP immunolocalization in the AA+CKD cohort, in both females and males. Ectopic renal and vascular calcification was observed in the AA+CKD group. Gene expression profiling in the kidney revealed that AA treatment modulates the immune and mineral metabolism pathways, while CKD superimposition induces a shift toward pro-inflammatory and pro-fibrotic responses, compromising renal and skeletal homeostasis. These findings underscore the importance of carefully evaluating HPP patients under treatment with mineral-targeted TNAP at risk of developing comorbid conditions associated with ectopic calcification.

  • Open Access

    Crosstalk between adipocytes and osteoblasts in regulating bone differentiation

    by Mariana Liessa Rovis Sanches, Cintia Kazuko Tokuhara, Flávia Amadeu de Oliveira, Talita Ventura, Adriano de Souza Pessoa, Flávia Godoy Iano, Mariana Rodrigues Santesso, Emanuelle Pangoni de Carvalho, Larissa Tercília Grizzo Thomassian, Marília Rabelo Buzalaf, et al.


  • Open Access

    Genetic reduction or deletion of osteopontin in osteomalacic Hyp mice fails to ameliorate dentoalveolar defects

    by Aonjittra Phanrungsuwan, Bella Donnelly, Jinju Kim, Jack Sweet, Flavia Amadeu de Oliveira, Do-Gyoon Kim, Eva S Liu, José Luis Millán, Marc D McKee, Brian L Foster

    X-linked hypophosphatemia (XLH) is caused by inactivating mutations in PHEX, leading to disturbed mineral metabolism, rickets, and osteomalacia. Dentoalveolar defects affecting dentin, cementum, and alveolar bone, contribute to dental abscesses and periodontal breakdown. Limited efficacy of current therapies for ameliorating XLH-associated dentoalveolar effects suggests mechanisms of disease that remain unchecked. Increased production and abnormal distribution of osteopontin (OPN) is thought to contribute to XLH-associated mineralization defects. Osteopontin is a secreted phosphoprotein and mineralization inhibitor, and a substrate of PHEX. To investigate the potential role of OPN in the pathology of XLH-associated dentoalveolar defects, a genetic approach was used to ablate or diminish Spp1/OPN in the Hyp mouse model of XLH. One or both Spp1 alleles in Hyp mice were deleted and tissues were analyzed at 60 d postnatally (dpn). Micro-CT showed no differences in volumes or densities of dentin and alveolar bone in Hyp mice lacking one or both Spp1 alleles, as compared to control Hyp mice. Histological assessment showed no improvements in cementum or periodontal ligament attachment, and dynamic mechanical analysis revealed no normalization of periodontal mechanical properties. While OPN may play a role in regulating dentoalveolar mineralization, diminishing OPN alone was not sufficient to substantially ameliorate XLH-associated defects.


  • Open Access

    Proof-of-principle for enhanced dentoalveolar mineralization using exogenous tissue-nonspecific alkaline phosphatase in the Hyp mouse model of X-linked hypophosphatemia

    by Aonjittra Phanrungsuwan, Bella Donnelly, Fatma F Mohamed, Kedith Sawangsri, Karli Belgya, Tamara N Kolli, Jinju Kim, Do-Gyoon Kim, Flavia Amadeu de Oliveira, Eva S Liu, et al.

    X-linked hypophosphatemia (XLH) is caused by mutations in the PHEX gene, which leads to increased levels of fibroblast growth factor 23 and hypophosphatemia, contributing to rickets, osteomalacia, and dentoalveolar defects, including severe dentin hypomineralization, thin cementum, and alveolar bone osteomalacia. Current XLH treatment options appear to have limited efficacy on dentoalveolar tissues, suggesting underlying disease mechanisms that remain unchecked. Increased production of inorganic pyrophosphate (PPi) and osteopontin (OPN), both mineralization inhibitors, has been posited to contribute to mineralization defects in XLH. The enzyme, tissue-nonspecific alkaline phosphatase (TNAP) reduces PPi levels via hydrolysis and inactivates OPN by dephosphorylation. Our previous study showed improved alveolar bone socket healing in Hyp mice administered mineralized tissue-targeted TNAP (TNAP-Fc-D10). We hypothesized that increased TNAP would partially ameliorate developmental mineralization defects in XLH by dually reducing PPi levels and dephosphorylating and inactivating OPN. In a proof-of-principle study to investigate pathological mechanisms, we delivered systemic (subcutaneous injection) and local (submucosal injection to mandibles) TNAP-Fc-D10 injections to the Hyp mutant mouse model of XLH from 7 to 60 d postnatal (dpn). While systemic delivery was ineffective at improving dentin or bone properties, micro-CT and histology analyses demonstrated that local delivery of TNAP-Fc-D10 increased dentin thickness, root length, alveolar bone volume, alveolar bone proper (ABP) volume and density, PDL attachment, and acellular cementum thickness, compared to control Hyp mice receiving a sham injection. Dynamic mechanical testing confirmed partially improved mechanical properties in locally treated vs untreated Hyp mice, suggesting incompletely improved periodontal function. Quantitative PCR revealed increased Dspp expression in molars of treated Hyp mice. In conclusion, we found TNAP administration reduced dentoalveolar defects in Hyp mice when delivered locally into dentoalveolar structures, proof-of-principle pointing to a pathological contribution by PPi and/or OPN and highlighting a promising adjunctive approach considering limitations of current treatment modalities.

  • Open Access

    ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia

    by Sonoko Narisawa, Flavia Amadeu de Oliveira, Cintia Kazuko Tokuhara, Elis J Lira dos Santos, Elena Fonfria, Jennifer Batson, Zhiliang Cheng, Ann Houston, Brian L Foster, José Luis Millán

    Hypophosphatasia (HPP) is caused by loss-of-function mutations in the human ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP), whose deficiency results in the accumulation of the calcification inhibitor inorganic pyrophosphate (PPi), resulting in skeletal and dental hypomineralization. Enzyme replacement with mineral-targeted TNAP (asfotase alfa) improves skeletal mineralization but the almost daily injections of this biologic can lead to injection site reactions and discontinuation of treatment. Since PPi is produced by the enzymatic action of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) from adenosine triphosphate (ATP), we tested if ENPP1 could be a druggable target for the development of an alternative treatment for HPP, particularly for the non-lethal later-onset forms of HPP, where enzyme replacement is not currently approved. We orally administered 30 and 100 mg/kg/day of an ENPP1 inhibitor, REV102, to the AlplPrx1/− mouse model of late-onset HPP, for 105 days and confirmed target engagement, as plasma PPi concentrations were markedly reduced. X-ray, micro-CT, and bone morphometry indicated improvement in appendicular skeletal mineralization. This study suggests that the adult HPP phenotype could benefit from oral administration of ENPP1 inhibitors.


  • Open Access

    Dentoalveolar defects and impaired alveolar bone healing in a neural crest directed conditional knockout mouse model of hypophosphatasia

    by F.F. Mohamed, A. Phanrungsuwan, F. Amadeu de Oliveira, J.L. Millán, B.L. Foster


  • Open Access

    The Multifarious Functions of Leukotrienes in Bone Metabolism

    by Flávia Amadeu de Oliveira, Cintia K. Tokuhara, Vimal Veeriah, João Paulo Domezi, Mariana R. Santesso, Tania M. Cestari, Talita M.O. Ventura, Adriana A. Matos, Thiago Dionísio, Marcel R. Ferreira, et al.

    Leukotrienes (LTs) are derived from arachidonic acid metabolism by the 5‐lipoxygenase (5‐LO) enzyme. The production of LTs is stimulated in the pathogenesis of rheumatoid arthritis (RA), osteoarthritis, and periodontitis, with a relevant contribution to bone resorption. However, its role in bone turnover, particularly the suppression of bone formation by modulating the function of osteoclasts and osteoblasts, remains unclear. We investigated the effects of LTs on bone metabolism and their impact on osteogenic differentiation and osteoclastogenesis using a 5‐LO knockout (KO) mouse model. Results from micro‐computed tomography (μCT) analysis of femur from 8‐week‐old 5‐LO‐deficient mice showed increased cortical bone and medullary region in females and males and decreased trabecular bone in females. In the vertebra, we observed increased marrow area in both females and males 5‐LO KO and decreased trabecular bone only in females 5‐LO KO. Immunohistochemistry (IHC) analysis showed higher levels of osteogenic markers tissue‐nonspecific alkaline phosphatase (TNAP) and osteopontin (OPN) and lower expression of osteoclastogenic marker tartrate‐resistant acid phosphatase (TRAP) in the femurs of 5‐LO KO mice versus wild‐type (WT). Alkaline phosphatase activity and mineralization assay results showed that the 5‐LO absence enhances osteoblasts differentiation and mineralization but decreases the proliferation. Alkaline phosphatase (ALP), Bglap, and Sp7 gene expression were higher in 5‐LO KO osteoblasts compared to WT cells. Eicosanoids production was higher in 5‐LO KO osteoblasts except for thromboxane 2, which was lower in 5‐LO–deficient mice. Proteomic analysis identified the downregulation of proteins related to adenosine triphosphate (ATP) metabolism in 5‐LO KO osteoblasts, and the upregulation of transcription factors such as the adaptor‐related protein complex 1 (AP‐1 complex) in long bones from 5‐LO KO mice leading to an increased bone formation pattern in 5‐LO–deficient mice. We observed enormous differences in the morphology and function of osteoclasts with reduced bone resorption markers and impaired osteoclasts in 5‐LO KO compared to WT osteoclasts. Altogether, these results demonstrate that the absence of 5‐LO is related to the greater osteogenic profile. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).


  • Open Access

    Dentoalveolar Alterations in an Adenine‐Induced Chronic Kidney Disease Mouse Model

    by Fatma F. Mohamed, Flavia Amadeu de Oliveira, Yuka Kinoshita, Riti R. Yalamanchili, Leena A. Eltilib, Natalie L. Andras, Sonoko Narisawa, Takashi Tani, Emily Y. Chu, José Luis Millán, et al.

    Chronic kidney disease (CKD) is characterized by kidney damage and loss of renal function. CKD mineral and bone disorder (CKD–MBD) describes the dysregulation of mineral homeostasis, including hyperphosphatemia and elevated parathyroid hormone (PTH) secretion, skeletal abnormalities, and vascular calcification. CKD–MBD impacts the oral cavity, with effects including salivary gland dysfunction, enamel hypoplasia and damage, increased dentin formation, decreased pulp volume, pulp calcifications, and altered jaw bones, contributing to clinical manifestations of periodontal disease and tooth loss. Underlying mechanisms are not fully understood, and CKD mouse models commonly require invasive procedures with high rates of infection and mortality. We aimed to characterize the dentoalveolar effects of an adenine diet (AD)‐induced CKD (AD–CKD) mouse model. Eight‐week‐old C57BL/6J mice were provided either a normal phosphorus diet control (CTR) or adenine and high‐phosphorus diet CKD to induce kidney failure. Mice were euthanized at 15 weeks old, and mandibles were collected for micro–computed tomography and histology. CKD mice exhibited kidney failure, hyperphosphatemia, and hyperparathyroidism in association with porous cortical bone in femurs. CKD mice showed a 30% decrease in molar enamel volume compared to CTR mice. Enamel wear was associated with reduced ductal components, ectopic calcifications, and altered osteopontin (OPN) deposition in submandibular salivary glands of CKD mice. Molar cusps in CKD mice were flattened, exposing dentin. Molar dentin/cementum volume increased 7% in CKD mice and pulp volume decreased. Histology revealed excessive reactionary dentin and altered pulp‐dentin extracellular matrix proteins, including increased OPN. Mandibular bone volume fraction decreased 12% and bone mineral density decreased 9% in CKD versus CTR mice. Alveolar bone in CKD mice exhibited increased tissue‐nonspecific alkaline phosphatase localization, OPN deposition, and greater osteoclast numbers. AD–CKD recapitulated key aspects reported in CKD patients and revealed new insights into CKD‐associated oral defects. This model has potential for studying mechanisms of dentoalveolar defects or therapeutic interventions. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).


  • Open Access

    Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP‐D10 Improves the Skeletal Phenotypes in Murine Models of Osteomalacia

    by Flavia Amadeu de Oliveira, Fatma F. Mohamed, Yuka Kinoshita, Sonoko Narisawa, Colin Farquharson, Koichi Miyake, Brian L Foster, Jose Luis Millan

    Hypophosphatasia (HPP), caused by loss‐of‐function mutations in the ALPL gene encoding tissue‐nonspecific alkaline phosphatase (TNAP), is characterized by skeletal and dental hypomineralization that can vary in severity from life‐threatening to milder manifestations only in adulthood. PHOSPHO1 deficiency leads to early‐onset scoliosis, osteomalacia, and fractures that mimic pseudo‐HPP. Asfotase alfa, a life‐saving enzyme replacement therapy approved for pediatric‐onset HPP, requires subcutaneous injections 3 to 6 times per week. We recently showed that a single injection of an adeno‐associated virus vector serotype 8 harboring TNAP‐D10 (AAV8‐TNAP‐D10) effectively prevented skeletal disease and prolonged life in Alpl−/− mice phenocopying infantile HPP. Here, we aimed to determine the efficacy of AAV8‐TNAP‐D10 in improving the skeletal and dental phenotype in the AlplPrx1/Prx1 and Phospho1−/− mouse models of late‐onset (adult) HPP and pseudo‐HPP, respectively. A single dose of 3 × 1011 vector genomes per body (vg/b) was injected intramuscularly into 8‐week‐old AlplPrx1/Prx1 and wild‐type (WT) littermates, or into 3‐day‐old Phospho1−/− and WT mice, and treatment efficacy was evaluated after 60 days for late‐onset HPP mice and after 90 days for Phospho1−/− mice. Biochemical analysis showed sustained serum alkaline phosphatase activity and reduced plasma PPi levels, and radiographic images, micro‐computed tomography (micro‐CT) analysis, and hematoxylin and eosin (H&E) staining showed improvements in the long bones in the late‐onset HPP mice and corrected scoliosis in the Phospho1−/− mice. Micro‐CT analysis of the dentoalveolar complex did not reveal significant changes in the phenotype of late‐onset HPP and pseudo‐HPP models. Moreover, alizarin red staining analysis showed that AAV8‐TNAP‐D10 treatment did not promote ectopic calcification of soft organs in adult HPP mice after 60 days of treatment, even after inducing chronic kidney disease. Overall, the AAV8‐TNAP‐D10 treatment improved the skeletal phenotype in both the adult HPP and pseudo‐HPP mouse models. This preclinical study will contribute to the advancement of gene therapy for the improvement of skeletal disease in patients with heritable forms of osteomalacia. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.